By Michael Dabaie

 

Ionis Pharmaceuticals Inc. (IONS) said Monday its partner Roche (RHHBY) enrolled the first patient in a pivotal study of RG6042 for Huntington's disease.

With the initiation of the study, Ionis said it earned a $35 million milestone payment.

Roche and Ionis are collaborating to develop antisense drugs to treat Huntington's disease. In total, Ionis has generated $135 million in up-front, milestone and license payments and is eligible to receive additional milestone payments as RG6042 progresses in development, as well as royalties.

Huntington's disease is a hereditary neurodegenerative disorder for which there is currently no approved disease-modifying treatment, Ionis said.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

January 28, 2019 07:53 ET (12:53 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Roche (QX) Charts.